4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $577.85M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.68M
Average 0.77M
FDMT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
4D Molecular Therapeutics, Inc.NASDAQ: FDMT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $64.98M rose 59.7% year over year, ahead of the +42.7% change in trailing-twelve-month research & development. Sequentially, it rose 12.8% from the prior quarter. Over 3 fiscal years it compounded at +34.6% a year.
Context
- Research & development amounted to 229.7% of revenue in FY2025, down 381659.5 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +59.7% holds above the trailing-twelve-month pace of +42.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 195.7M USD
- Year-over-year change
- +38.5%
- 4-year CAGR
- +33.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 195.7M | +38.5% |
| FY2024 | 2024-12-31 | 141.3M | +45.5% |
| FY2023 | 2023-12-31 | 97.1M | +21.0% |
| FY2022 | 2022-12-31 | 80.25M | +30.8% |
| FY2021 | 2021-12-31 | 61.36M | — |
Research & Development vs competitors
How FDMT compares with its peers on the latest reported figures
- FDMT's LTM Mar 2026 research & development of $219.98M is the 2nd highest of the 8 companies compared; the peer median is $128.82M.
- Its year-over-year change of +42.7% is the 2nd highest of 8, against a peer median of +9.2%.
- Research & development amounts to 249.3% of revenue for FDMT, versus a peer median of 260.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $228.65M | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $132.76M | -4.7% | -10.7% | 733.7% | |
| LTM Mar 2026 | $128.82M | +9.2% | +14.8% | 161.5% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $62.33M | -17.5% | +9.1% | — |
| LTM Mar 2026 | $41.48M | +19.1% | -10.9% | 928.9% | |
| LTM Mar 2026 | $26.43M | -28.8% | -2.5% | 181.7% | |
| Peer median (excluding FDMT) | $128.82M | +9.2% | -2.0% | 260.4% | |
Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.04M | 3.13M | 20.72M | 37K | 85.21M |
| Cost of Revenue | 61.36M | 80.25M | 97.1M | 141.3M | 7.63M |
| Gross Profit | (43.32M) | (77.12M) | (76.37M) | (141.26M) | 77.58M |
| Gross Margin | -240.2% | -2464.8% | -368.5% | -381789.2% | 91.1% |
| Research & Development | 61.36M | 80.25M | 97.1M | 141.3M | 195.7M |
| Selling, General & Admin | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M |
| Operating Expenses | 28.01M | 32.91M | 36.49M | 46.58M | 237.13M |
| Depreciation & Amortization | 1.52M | 2.4M | 4.2M | 6.71M | 7.63M |
| EBITDA | (69.79M) | (105.09M) | (96.63M) | (154.16M) | (132.48M) |
| EBITDA Margin | -386.9% | -3358.6% | -466.3% | -416656.8% | -155.5% |
| Operating Income | (71.33M) | (110.03M) | (112.87M) | (187.84M) | (159.55M) |
| Operating Margin | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Interest Income | 137K | 2.57M | 12.21M | 27.05M | 19.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16K | 2.54M | 12.03M | 26.97M | 19.44M |
| Income Before Tax | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Pre-Tax Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Net Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| EPS (Basic) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| EPS (Diluted) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| Weighted Avg Shares | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
| Weighted Avg Shares (Diluted) | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
Intrinsic Alpha fair value
Locked
Current Price
$10.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.